Bicycle Therapeutics (BCYC) Total Non-Current Liabilities (2018 - 2026)

Bicycle Therapeutics' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $97.1 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 31.83% year-over-year to $97.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.1 million (down 31.83% YoY) and the FY2025 annual result came in at $106.6 million, down 34.48% from the prior year.
• Total Non-Current Liabilities was $97.1 million for Q1 2026 at Bicycle Therapeutics, down from $106.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $229.7 million in Q2 2023 and bottomed at $97.1 million in Q1 2026.
• A 5-year average of $159.2 million and a median of $159.8 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities surged 75.6% — and 2025, when it plunged 34.48%.
• Bicycle Therapeutics' Total Non-Current Liabilities stood at $136.0 million in 2022, then soared by 61.65% to $219.8 million in 2023, then retreated by 26.0% to $162.7 million in 2024, then tumbled by 34.48% to $106.6 million in 2025, then retreated by 8.9% to $97.1 million in 2026.
• Business Quant data shows BCYC's Total Non-Current Liabilities at $97.1 million in Q1 2026, $106.6 million in Q4 2025, and $144.4 million in Q3 2025.